Enhanced binding affinity for FcγRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity

被引:145
作者
Masuda, Kazuhiro [1 ]
Kubota, Tsuguo [1 ]
Kaneko, Etsuji [1 ]
Iida, Shigeru [1 ]
Wakitani, Masako [1 ]
Kobayashi-Natsume, Yukari [1 ]
Kubota, Ai [1 ]
Shitara, Kenya [1 ]
Nakamura, Kazuyasu [1 ]
机构
[1] Kyowa HakkoKogyo Co Ltd, Div Mol Immunol, BioFrontier Labs, Machida, Tokyo 1948533, Japan
关键词
antibody-dependent cellular cytotoxicity (ADCC); Fc gamma RIIIa; NK cell; fucose;
D O I
10.1016/j.molimm.2007.02.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Antibody-dependent cellular cytotoxicity (ADCC) is considered to be an important therapeutic function for clinical efficacy of monoclonal antibodies. Recent studies have revealed two methods to increase binding affinity for Fc-yRIIIa and enhance ADCC more efficiently for antibodies: (i) fucose removal from antibody N-linked complex oligosaccharides and (ii) amino acid mutations in the antibody Fc region. In this study, we compare the biological activities of the methods of generating high ADCC antibodies. We used a fucose-negative antibody and two antibodies with sets of mutations, demonstrated previously to optimally enhance ADCC using the chimeric anti-CD20 antibody, rituximab, as the model. Both amino acid mutant antibodies showed a significantly higher affinity for recombinant Fc-yRIIIa than fucose-negative antibody when compared using biosensor analysis. The removal of fucose from the antibodies bearing amino acid mutations exhibited a further enhancement of binding to recombinant Fc-gamma RIIIa and significantly increased binding to natural killer (NK) cells. Despite the differences manifested in binding for the Fc gamma R, ADCCs were indistinguishable between methods and even when the methods were combined. These results indicate that the affinity of binding to Fc gamma RIIIa does not predict ADCC beyond a certain threshold and that each method alone is sufficient to induce maximal ADCC of the antibody. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3122 / 3131
页数:10
相关论文
共 43 条
[1]   The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus [J].
Anolik, JH ;
Campbell, D ;
Felgar, RE ;
Young, F ;
Sanz, I ;
Rosenblatt, J ;
Looney, RJ .
ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :455-459
[2]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[3]   Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen [J].
Chen, Y ;
Wiesmann, C ;
Fuh, G ;
Li, B ;
Christinger, HW ;
McKay, P ;
de Vos, AM ;
Lowman, HB .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (04) :865-881
[4]  
CLYNES RA, 2005, NAT MED, V4, P443
[5]   Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents [J].
Cragg, MS ;
Glennie, MJ .
BLOOD, 2004, 103 (07) :2738-2743
[6]   Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship [J].
Dall'Ozzo, S ;
Tartas, S ;
Paintaud, G ;
Cartron, G ;
Colombat, P ;
Bardos, P ;
Watier, H ;
Thibault, G .
CANCER RESEARCH, 2004, 64 (13) :4664-4669
[7]  
Davies J, 2001, BIOTECHNOL BIOENG, V74, P288, DOI 10.1002/bit.1119
[8]   Complement activation determines the therapeutic activity of rituximab in vivo [J].
Di Gaetano, N ;
Cittera, E ;
Nota, R ;
Vecchi, A ;
Grieco, V ;
Scanziani, E ;
Botto, M ;
Introna, M ;
Golay, J .
JOURNAL OF IMMUNOLOGY, 2003, 171 (03) :1581-1587
[9]   Allelic polymorphisms in the FcγRIIC gene can influence its function on normal human natural killer cells [J].
Ernst, LK ;
Metes, D ;
Herberman, RB ;
Morel, PA .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2002, 80 (04) :248-257
[10]   The carbohydrate at FcγRIIIa Asn-162 -: an element required for high affinity binding to non-fucosylated IgG glycoforms [J].
Ferrara, C ;
Stuart, F ;
Sondermann, P ;
Brükner, P ;
Umaña, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (08) :5032-5036